Opus Genetics (IRD) Debt Ratio (2021 - 2026)

Opus Genetics' (IRD) quarterly Debt Ratio came in at 0.02 in Q1 2026, down 20.17% on a QoQ basis from 0.02 in Q4 2025.

Opus Genetics (IRD) Debt Ratio (2021 - 2026) Analysis & Trends

Opus Genetics (IRD) has 4 years of Debt Ratio data on file, last reported at 0.02 in Q1 2026.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.02 in Q1 2026; TTM through Mar 2026 was 0.02, a N/A change from a year earlier, with the FY2025 full-year figure at 0.02, changed N/A from the prior year.
Debt Ratio for Q1 2026 stood at 0.02, down from 0.02 in the prior quarter.
Over the last five years, Debt Ratio for IRD reached as high as 0.03 in Q3 2025 and fell as low as 0.01 in Q1 2022.
Historically, Debt Ratio has averaged 0.02 across 3 years, with a median of 0.02 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	1.41
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	0.11
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	0.05
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Opus Genetics	263.72 Mn	203.72 Mn	-	0.02

Download Data